source
- Formation Bio raises $600 million fund to expand AI-driven drug licensing and testing modelFormation Bio, an AI-focused biotech that builds value by acquiring external drug assets, developing them and then transferring them to partners, announced a new financing round. The company secur…
- Analysts Question Biogen's Lupus Drug Litifilimab Ahead of Key Phase 3 ReadoutsAnalysts pressed Biogen CEO Chris Viehbacher during a recent call, focusing on the company's late‑stage pipeline. The discussion centered on litifilimab, Biogen’s experimental lupus therapy, with…